China and Germany to join forces over SARS
The epidemic of severe acute respiratory syndrome (SARS) has sparked a host of unexpected alliances in the global research community.
In this article, Alison Abbott reports on one such alliance, between Jiang Hua-Liang, head of the Drug Discovery and Design Center at the Shanghai Institute of Materia Medica, and Rolf Hilgenfeld, a structural biologist at the University of Lübeck in Germany.
The researchers hopes that the combination of Hilgenfeld's expertise in coronaviruses and Jiang's knowledge of using supercomputers to screen drug candidates will allow them to develop new leads for anti-SARS drugs. Their plans will be turned into a formal funding proposal to be presented to the Sino-German Centre for Science Promotion, which is jointly financed by research agencies in Germany and China.